ClinicalTrials.Veeva

Menu

Traditional Chinese Medicine for Severe COVID-19

X

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Status and phase

Unknown
Phase 3

Conditions

COVID-19

Treatments

Drug: Traditional Chinese Medicine Prescription

Study type

Interventional

Funder types

Other

Identifiers

NCT04323332
2020XLA015-1

Details and patient eligibility

About

In December 2019, a new type of pneumonia, COVID-2019 outbroke in Wuhan ,China, and currently the infected has been reported in more than at least 75 countries.

Patients with severe COVID-19 have rapid disease progression and high mortality rate. This may attribute to the excessive immune response caused by cytokine storm. Strategies based on anti-virus drugs and treatments against symptoms have now been employed. However, these managements can't effectively treat the lethal lung injury and uncontrolled immune responses, especially in the elderly with severe COVID-19. Traditional Chinese Medicine (TCM), which treats the disease from anther perspective, has achieved satisfactory results. National Health Commission of China released a series of policies to enhance the administration of TCM prescriptions.

This study is aimed to evaluate the efficacy and safety of Traditional Chinese Medicine as an adjuvant treatment for severe COVID-19.

Enrollment

50 estimated patients

Sex

All

Ages

Under 85 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  1. Patients were diagnosed as severe COVID-19 according to the Coronavirus disease (COVID-19) Treatment Guidance (Six edition)
  2. Patients received a combined treatment of TCM and conventional therapy, or only conventional therapy.

Key Exclusion Criteria:

  1. Age >85 years
  2. After cardiopulmonary resuscitation
  3. Patients combined with other organ failure or conditions need ICU monitoring and treatment, such as severe liver disease, severe renal dysfunction, upper gastrointestinal hemorrhage, disseminated intravascular coagulation.
  4. Respiratory failure and need mechanical ventilation

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

50 participants in 2 patient groups

Traditional Chinese Medicine
Experimental group
Description:
TCM prescription and conventional treatments
Treatment:
Drug: Traditional Chinese Medicine Prescription
Control
No Intervention group
Description:
conventional treatments

Trial contacts and locations

1

Loading...

Central trial contact

Hao Li, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems